Division of Bristol-Myers Squibb Co.
Latest From Inhibitex Inc.
While a dwindling patient base and pricing pressures are depleting the market opportunity in hepatitis C, Merck's decision also may result from regulatory dialogue potentially delaying the start of a Phase III study.
Interim Phase IIa data of a triple combination from J&J and Achillion shows 100% SVR at end of treatment with a six-week dosing regimen. No currently approved HCV therapy has such a short treatment duration.
There aren't many privately held UK-based pharmaceutical companies that can boast of appointing an inventor behind one of the world's biggest selling drugs to its management team. But Nucana's new CSO is Professor Chris McGuigan, the man behind ProTides, a technology used in drugs such as Gilead Sciences' Sovaldi (sofosbuvir). Here he tells Scrip what prompted him to cut down on his academic commitments for the first time in his career to take up a management position at a little-known oncology firm.
Gilead issues “Dear Healthcare Provider” letter outlining nine cases of bradycardia in patients who received amiodarone in combination with one of its HCV polymerase inhibitors; FDA has updated labeling for both drugs.
- Large Molecule
- Therapeutic Areas
- Infectious & Viral Diseases
- North America
- Parent & Subsidiaries
- Bristol-Myers Squibb Co.
- Senior Management
- Peter J Azzarello, VP, Fin.
- Contact Info
Phone: (678) 746-1100
9005 Westside Pkwy.
Alpharetta, GA 30009
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.